Active specific immunotherapy of malignant melanoma
Lotem, M.; Shiloni, E.; Ingber, A.; Peretz, T.
Harefuah 133(3-4): 122-126
1997
ISSN/ISBN: 0017-7768 PMID: 9332080 Document Number: 471621
Document emailed within 1 workday
Related Documents
Mutzner, P.A.; Stuhlmiller, G.M.; Seigler, H.F.; Stumpf, W.E.; Sar, M. 1981: Basis for a specific-active immunotherapy in malignant melanoma Schweizerische Medizinische Wochenschrift 111(36): 1322-1325Romodanov, S.A.; Zatula, D.G.; Lisianyĭ, N.I.; Glavatskiĭ, A.Ia.; Prosvirneva, G.M. 1986: Efficacy of experimental active specific immunotherapy and immunoprevention of malignant gliomas of the brain Zhurnal Voprosy Neirokhirurgii Imeni N. N. Burdenko 1986(3): 18-23
Kristensen, E. 1976: Use of immunotherapy in the treatment of malignant melanoma of the skin Ugeskrift for Laeger 138(8): 468-473
Kovarík, J.; Ninger, E.; Mechl, Z.; Zemanová, D.; Lauerová, L.; Sopková, B.; Svejda, J.; Bacovský, B.; Bártová, A.; Bártek, J. 1983: Immunotherapy and immune competence of patients with malignant melanoma Czechoslovak Medicine 6(3): 172-174
Schirrmacher, V.; von Hoegen, P.; Heicappell, R. 1989: Virus modified tumor cell vaccines for active specific immunotherapy of micrometastases: expansion and activation of tumor-specific T cells Progress in Clinical and Biological Research 288: 391-399
Dufour, F.D.; Morton, D.L. 1977: Induction of melanoma specific monocyte cytotoxicity in patients receiving BCG immunotherapy Surgical Forum 28: 165-167
Spitler, L.E.; Wong, P.; Sagebiel, R. 1978: Combined immunotherapy of malignant melanoma. Unusual survival following cerebral metastasis Archives of Dermatology 114(10): 1501-1504
Mocellin, S. 2005: Priming anticancer active specific immunotherapy with dendritic cells Current Opinion in Investigational Drugs 6(6): 576-581
Grinevich, I.A. 1991: Nonspecific active immunotherapy in the combined treatment of malignant neoplasms Vrachebnoe Delo 5: 8-11
Hanna, M.G.; Peters, L.C.; Hoover, H.C. 1989: Fundamentals of active specific immunotherapy of cancer using BCG-tumor cell vaccines Progress in Clinical and Biological Research 310: 51-65
Castello, G.; D'Alessio, V. 1991: Active specific immunotherapy of cancer using anti-idiotypic monoclonal antibodies La Clinica Terapeutica 137(3): 155-167
Miura, T.; Ishikawa, S. 1970: Malignant melanoma--synopses from the seminar on malignant melanoma by International Group for the Clinical Study of Melanoma Gan no Rinsho. Japan Journal of Cancer Clinics 16(11): 1064-1070
Morton, D.L. 2004: Immune response to postsurgical adjuvant active immunotherapy with Canvaxin polyvalent cancer vaccine: correlations with clinical course of patients with metastatic melanoma Developments in Biologicals 116: 209
Ashley, M.P.; Zbar, B.; Hunter, J.T.; Rapp, H.J.; Sugimoto, T. 1980: Adjuvant-antigen requirements for active specific immunotherapy of microscopic metastases remaining after surgery Cancer Research 40(11): 4197-4203
Yamasaki, T.; Kikuchi, H. 1989: An experimental approach to specific adoptive immunotherapy for malignant brain tumors Nihon Geka Hokan. Archiv für Japanische Chirurgie 58(6): 485-492
Arlen, M.; Hollinshead, A.; Scherrer, J. 1977: Tumor-specific immunity in patients with malignant melanoma Surgical Forum 28: 168-169
Kalafut, F.; Cernák, A.; Pham Manh Hung 1979: Detection of specific immunoreactivity by LAi assay in patients with malignant melanoma of uveal tissue Neoplasma 26(3): 299-305
Grossmann, A.; Rameken, M.; Klapdor, R. 1997: Active-specific immunotherapy of pancreatic carcinoma: usefulness of human pancreatic carcinomas in preparing autologous tumor vaccines Anticancer Research 17(4b): 3117-3119
Shannan, B.; Seifert, M.; Leskov, K.; Boothman, D.; Pföhler, C.; Tilgen, W.; Reichrath, J. 2006: Clusterin (CLU) and melanoma growth: CLU is expressed in malignant melanoma and 1,25-dihydroxyvitamin D3 modulates expression of CLU in melanoma cell lines in vitro Anticancer Research 26(4a): 2707-2716
Chess, L.; Bock, G.N.; Ungaro, P.C.; Buchholz, D.H.; Mardiney, M.R. 1973: Immunologic effects of BCG in patients with malignant melanoma: specific evidence for stimulation of the 'secondary' immune response Journal of the National Cancer Institute 51(1): 57-65